UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 14, 2014
HEALTH ENHANCEMENT PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
Nevada | | 000-30415 | | 87-0699977 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
2804 Orchard Lake Road, Suite 202, Keego Harbor Michigan 48320
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code(248) 452-9866
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
.Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
.Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
.Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
.Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07
Submission of Matters to a Vote of Security Holders
At the annual meeting of the shareholders of Health Enhancement Products, Inc. (the “Company”) on October 14, 2014, shareholders: (1) elected elect five members of the board of directors, each to serve until the Annual Meeting of shareholders in 2015 and until his respective successor is elected and qualified; (2) approved an amendment to the Company’s Articles of Incorporation changing the name of the Company to Zivo Bioscience, Inc.; (3) approved (on an advisory basis) the compensation of the Company’s named executive officers; and (4) approved (on an advisory basis) whether an advisory vote on the compensation of our named executive officers should occur once every one, two or three years. Approximately 53% of our outstanding shares, exclusive of broker non-votes, were cast. The results of the voting are shown below. In view of such voting results and other factors, the Company’s Board of Directors (“Board”) determined at its meeting on October 14, 2014, that the Company will hold advisory say-on-pay votes on a three year basis until the next required non-binding advisory vote on the frequency of shareholder votes on executive compensation. The next required non-binding advisory vote regarding the frequency interval will be in six years, although an earlier vote regarding such frequency interval may be held at the Board’s discretion.
Proposal 1 – Election of Directors
| | | | |
Nominees | Votes For | Against | Abstentions | Broker Non-Votes |
Thomas K. Cox | 34,566,488 | 642,000 | 3,400 | 58,662,304 |
Nola E. Masterson | 35,208,488 | 0 | 3,400 | 58,662,304 |
Philip M. Rice II | 34,451,488 | 757,000 | 3,400 | 58,662,304 |
Christopher D. Maggiore | 35,016,697 | 191,791 | 3,400 | 58,662,304 |
John B. Payne | 35,208,488 | 0 | 3,400 | 58,662,304 |
Proposal 2 – Approval of an Amendment to the Company’s Articles of Incorporation Changing the Name of the Company to Zivo Bioscience, Inc.
| | | |
Votes For | Against | Abstentions | Broker Non-Votes |
93,013,070 | 507,069 | 354,053 | 0 |
Proposal 3 – Approval (on an advisory basis) of the Compensation of Named Executive Officers
| | | |
Votes For | Against | Abstentions | Broker Non-Votes |
26,902,722 | 6,896,013 | 1,413,153 | 58,662,304 |
Proposal 4 – Advisory Approval as to the Frequency of Having an Advisory Vote on the Compensation of Named Executive Officers
| | | | |
Every One Year | Every Two Years | Every Three Years | Abstentions | Broker Non-Votes |
12,308,902 | 6,468,210 | 15,186,322 | 1,248,454 | 58,662,304 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH ENHANCEMENT PRODUCTS, INC.
Date: October 16, 2014
By:
/s/ PHILIP M. RICE, II
Philip M. Rice, II
Chief Financial Officer
3
